|[June 12, 2014]
Targeted Medical Pharma Appoints Two New Independent Members to the Board of Directors
LOS ANGELES --(Business Wire)--
Medical Pharma, Inc. (OTCQB: TRGM), today announced the addition of
two independent members to the Company's board of directors. The Company
welcomes back health care specialist Kerry Weems to the board as an
independent director and chairman of the Nominating and Governance
Committee, as well as corporate finance expert Paul Pelosi, Jr. as an
A nationally respected expert in health policy and government finance,
Mr. Weems has served with distinction in the field of health care,
including nearly 28 years in the Federal government, as Acting
Administrator of the Centers for Medicare and Medicaid Services (CMS).
Mr. Weems is currently Chief Executive Officer of TwinMed, a national
medical supply distributor in Los Angeles.
Mr. Paul Pelosi, Jr., has many years of experience in advising companies
in the areas of finance, infrastructure, and sustainability. Mr. Pelosi
has background in business law, public policy, the public securities
markets, and has worked with numerous emerging microcap companies to
develop sound business protocols. Mr. Pelosi has been a private investor
and an independent adviser to emerging companies, including NASA Ames
Research Center, Global Emerging Markets and AirPatrol Corporation. Mr.
Pelosi graduated from Georgetown Law Center, has been a member of the
California State Bar since 1996, and Real Estate Broker since 2002.
Twitter (News - Alert): a rel="nofollow" href="http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2FTMedPharma&esheet=50885680&newsitemid=20140612006432&lan=en-US&anchor=%40tmedpharma&index=2&md5=0063efdd43d2f66d234480c23d851782" rel="nofollow">@tmedpharma
Facebook (News - Alert): https://www.facebook.com/TargetedMedicalPharma
About Targeted Medical Pharma, Inc.
Medical Pharma, Inc. is a Los Angeles-based biotechnology company
that develops medical
foods for the treatment of chronic disease, including pain
syndromes, peripheral neuropathy, hypertension, obesity, sleep and
cognitive disorders. The company also develops a line of dietary
supplements designed to support health and wellness. The company
manufactures 10 proprietary medical foods, and recently launched its
first dietary supplement, Clearwayz™.
The products are sold directly to physicians and pharmacies in the
U.S. The company also is developing nutrient-based systems for oral
stimulation of progenitor stem cells that differentiate into neurons,
red blood cells, pituitary hormones including IGF-I.
Forward Looking Statement
This press release may contain forward-looking statements related to
Targeted Medical Pharma's business strategy, outlook, objectives, plans,
intentions or goals. The words "may," "will," "should," "plans,"
"explores," "expects," "anticipates," "continue," "estimate," "project,"
"intend," and similar expressions, identify forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of
1995, but their absence does not mean that the statement is not
forward-looking. These statements are not guarantees of future
performance and are subject to certain risks, uncertainties, and
assumptions that are difficult to predict. Actual results could differ
materially. Targeted Medical Pharma expressly disclaims any obligation
or undertaking to update or revise any forward-looking statement
contained herein to reflect any change in the company's expectations
with regard thereto or any change in events, conditions or circumstances
upon which any statement is based.
[ Back To TMCnet.com's Homepage ]